Oxidative stress in Huntington's disease knock-in striatal cells

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-02-24

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Current Pharmaceutical Design

  2016cited by this paper
• in vitro and in vivo

  2016cited by this paper
• Oxygen Radicals

  2014cited by this paper
• Progress in Neurobiology

  2014cited by this paper
• IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice

  2014cited by this paper
• The Predicted Molecular Weight of Nrf2: It Is What It Is Not

  2013cited by this paper
• Dimethyl fumarate: a Janus-faced substance?

  2013cited by this paper
• Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics

  2013cited by this paper
• Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

  2013cited by this paper
• Factors Affecting Aggregate Formation in Cell Models of Huntington’s Disease and Amyotrophic Lateral Sclerosis

  2013cited by this paper
• BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival

  2013cited by this paper
• Vesicular glycolysis provides on-board energy for fast axonal transport.

  2013cited by this paper
• Dysfunctional mitochondrial respiration in the striatum of the Huntington’s disease transgenic R6/2 mouse model

  2013cited by this paper
• S-Nitrosylation of Dynamin-Related Protein 1 Mediates Mutant Huntingtin-Induced Mitochondrial Fragmentation and Neuronal Injury in Huntington's Disease

  2013cited by this paper
• Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

  2013cited by this paper
• Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection.

  2013cited by this paper
• IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux.

  2012cited by this paper
• Early Alterations of Brain Cellular Energy Homeostasis in

  2012cited by this paper
• Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

  2012cited by this paper
• An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity

  2012cited by this paper
• Wilms Tumor Gene on X Chromosome (WTX) Inhibits Degradation of NRF2 Protein through Competitive Binding to KEAP1 Protein*

  2012cited by this paper
• Selenium-induced antioxidant protection recruits modulation of thioredoxin reductase during excitotoxic/pro-oxidant events in the rat striatum.

  2012cited by this paper
• Dysregulation of Mitochondrial Calcium Signaling and Superoxide Flashes Cause Mitochondrial Genomic DNA Damage in Huntington Disease*

  2012cited by this paper
• Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)

  2012cited by this paper
• Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition.

  2012cited by this paper
• Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.

  2012cited by this paper
• The many faces of insulin-like peptide signalling in the brain

  2012cited by this paper
• Toward understanding Machado-Joseph disease.

  2012cited by this paper
• Neuroprotective effects of creatine

  2011cited by this paper
• FK506 ameliorates cell death features in Huntington's disease striatal cell models.

  2011cited by this paper
• Sirt1 mediates neuroprotection from mutant huntingtin by activation of TORC1 and CREB transcriptional pathway

  2011cited by this paper
• IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.

  2011cited by this paper
• Value of Invertebrate Genetics and Biology to Develop Neuroprotective and Preventive Medicine in Huntington’s Disease

  2011cited by this paper
• Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

  2011cited by this paper
• Inositol Hexakisphosphate Kinases Induce Cell Death in Huntington Disease

  2011cited by this paper
• MUTANT HUNTINGTIN BINDS THE MITOCHONDRIAL FISSION GTPASE DRP1 AND INCREASES ITS ENZYMATIC ACTIVTY

  2011cited by this paper
• PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease

  2011cited by this paper
• Advances in Experimental Medicine and Biology

  2011cited by this paper
• Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington’s disease provides in vivo evidence for impaired energy metabolism

  2011cited by this paper
• Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway.

  2011cited by this paper
• Bioenergetic dysfunction in Huntington's disease human cybrids.

  2011cited by this paper
• Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

  2010cited by this paper
• Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism.

  2010cited by this paper
• Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease

  2010cited by this paper
• Huntington’s Disease Pathogenesis

  2010cited by this paper
• Cell Death

  2010cited by this paper
• Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli

  2010cited by this paper
• Nrf2 signaling and cell survival.

  2010cited by this paper
• Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.

  2010cited by this paper
• Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo*

  2010cited by this paper
• Activation of NRF2 by Nitrosative Agents and H2O2 Involves KEAP1 Disulfide Formation*

  2010influential reference
• Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease

  2010cited by this paper
• Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases

  2009cited by this paper
• CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

  2009cited by this paper
• NRF2 Cysteine Residues Are Critical for Oxidant/Electrophile-Sensing, Kelch-Like ECH-Associated Protein-1-Dependent Ubiquitination-Proteasomal Degradation, and Transcription Activation

  2009cited by this paper
• Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.

  2009cited by this paper
• Protective Effect of Tert-Butylhydroquinone on the Quinolinic-Acid-Induced Toxicity in Rat Striatal Slices: Role of the Nrf2-Antioxidant Response Element Pathway

  2009cited by this paper
• Acetylation of Nrf2 by p300/CBP Augments Promoter-Specific DNA Binding of Nrf2 during the Antioxidant Response

  2009cited by this paper
• Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism.

  2009cited by this paper
• MOLECULAR AND CELLULAR BIOLOGY

  2009cited by this paper
• Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

  2009cited by this paper
• The basal flux of Akt in the mitochondria is mediated by heat shock protein 90

  2009cited by this paper
• Modifications of Superoxide Dismutase (SOD1) in Human Erythrocytes

  2009cited by this paper
• Kaempferol protects against rat striatal degeneration induced by 3‐nitropropionic acid

  2009cited by this paper
• Phosphorylation of Nrf2 at Multiple Sites by MAP Kinases Has a Limited Contribution in Modulating the Nrf2-Dependent Antioxidant Response

  2009cited by this paper
• Bulbar and spinal muscular atrophy (Kennedy’s disease): a review

  2009cited by this paper
• Cytoprotective Nrf2 Pathway Is Induced In Chronically Txnrd 1-Deficient Hepatocytes

  2009cited by this paper
• N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking

  2008cited by this paper
• Radical-free biology of oxidative stress.

  2008cited by this paper
• Insulin stimulation of gamma-glutamylcysteine ligase catalytic subunit expression increases endothelial GSH during oxidative stress: influence of low glucose.

  2008cited by this paper
• Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE.

  2008cited by this paper
• Weight loss in Huntington disease increases with higher CAG repeat number

  2008cited by this paper
• Nuclear Respiratory Factor 1 Regulates All Ten Nuclear-encoded Subunits of Cytochrome c Oxidase in Neurons*

  2008cited by this paper
• Brain insulin.

  2008cited by this paper
• A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

  2008cited by this paper
• Fission and selective fusion govern mitochondrial segregation and elimination by autophagy

  2008cited by this paper
• Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H‐1,2‐dithiole‐3‐thione

  2008cited by this paper
• Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease

  2008cited by this paper
• Instability of expanded CAG/CAA repeats in spinocerebellar ataxia type 17

  2008cited by this paper
• Transcriptional paradigms in mammalian mitochondrial biogenesis and function.

  2008cited by this paper
• Cytochrome C and caspase-9 expression in Huntington’s disease

  2007cited by this paper
• Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain.

  2007cited by this paper
• The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.

  2007cited by this paper
• Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.

  2007cited by this paper
• [Oxidative stress].

  2007cited by this paper
• Mechanisms of Copper Ion Mediated Huntington's Disease Progression

  2007cited by this paper
• Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease.

  2007cited by this paper
• Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.

  2007cited by this paper
• Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2.

  2007cited by this paper
• Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.

  2006cited by this paper
• Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG

  2006cited by this paper
• Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species.

  2006cited by this paper
• Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.

  2006cited by this paper
• The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity.

  2006cited by this paper
• Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH.

  2006cited by this paper
• Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.

  2006cited by this paper
• Disruption of ShcA signaling halts cell proliferation--characterization of ShcC residues that influence signaling pathways using yeast.

  2006cited by this paper
• Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

  2006cited by this paper
• Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells

  2006cited by this paper
• Nrf2 Possesses a Redox-sensitive Nuclear Exporting Signal in the Neh5 Transactivation Domain*

  2006cited by this paper

• Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions

  2021cites this paper
• Dynamin‐Related Protein 1 Promotes Mitochondrial Fission and Contributes to The Hippocampal Neuronal Cell Death Following Experimental Status Epilepticus

  2016cites this paper